關鍵數據
0.917今開
0.960最高
2.04K成交量
0.74本益比TTM
虧損本益比動
--股利TTM
0.01%換手率
0.920昨收
0.893最低
1.88K成交額
虧損本益比靜
2.53市淨率
0.00%股息率 TTM
-46.30%ROA
1.38552週最高
0.03量比
-53.95M淨利潤
44.29M總股本
1.2170每股盈餘TTM
0.79Beta
-775.14%ROE
0.50052週最低
7.28%振幅
61.74%毛利率
39.86M總市值
0.23回報/風險
4.80%風險率

即將為您帶來更多新聞,敬請期待。 。 。
Elutia Inc評分
0.12與上次評分對比預測8.00
財務診斷6.44
技術分析5.31
公司估值9.56
機構認同度3.00
風險評估3.01
分析師評級
買入評級
5.000目標均價
+497.30%漲幅空間
Elutia Inc 最新財報電話會記錄
Elutia (ELUT) 2026年第三季法說會:NXT 41X 的 FDA 遞件如期推進
Elutia 2026年第三季營收成長20%至110萬美元,在此之際,該公司正準備向FDA提交NXT 41X申請文件,並在未進行股權發行的情況下增加了2,600萬美元資金。
財務指標
貨幣: USD

由於公司未披露,未能獲取相關數據
貨幣: USD

由於公司未披露,未能獲取相關數據
Elutia Inc 簡介
Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Women’s Health and Cardiovascular markets. In Women’s Health, it offers SimpliDerm, a novel biological matrix that leverages the inherent science of natural healing processes. SimpliDerm's design uses human-based hydrated acellular dermal matrix (ADM), which mitigates inflammation and enhances tissue incorporation. In Cardiovascular, it sells its specialized porcine small intestine submucosa for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population. It is focused on advancing NXT-41x, a biomatrix that directly addresses the root causes of reconstruction infections following mastectomy. NXT-41x combines biologics and extended antibiotic release to provide protection while supporting tissue regeneration.
行業藥品
公司代碼ELUT
員工數量51
國家United States of America
持股情況
| 持股股東 | 佔比 |
|---|
| Highcape Partners, L.P. | 11.26% |
|---|
| Nantahala Capital Management, LLC | 7.20% |
|---|
| SilverArc Capital Management, LLC | 6.22% |
|---|
| AIGH Capital Management, LLC. | 6.00% |
|---|
| 股東類型 | 佔比 |
|---|
| Private Equity | 17.26% |
|---|
| Hedge Fund | 16.99% |
|---|
| Investment Advisor | 11.40% |
|---|
| Investment Advisor/Hedge Fund | 3.46% |
|---|
常見問題
Elutia Inc(ELUT)的當前股價是多少?
Elutia Inc(ELUT)的當前股價是 0.92。
Elutia Inc股票的52週最高點是1.39。
Elutia Inc股票的52週最低點是0.50。
現在Elutia Inc(ELUT)的股票是買入、持有還是賣出?
根據分析師評級,Elutia Inc(ELUT)的總體評級為買入,目標價格為5.00。
Elutia Inc(ELUT)股票的每股收益(EPS TTM)是多少
Elutia Inc(ELUT)股票的每股收益(EPS TTM)是1.22。